Renal Insufficiency,ChronicDietary Intake PatternsMalnutritionFrailtyCognitive DysfunctionCKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder
Study summary
This prospective cohort study aims to investigate how kidney function decline affects multiple body systems and how personalized nutrition can help maintain health and slow disease progression. About 1,800 adults with reduced kidney function but not on dialysis will be followed over time at Huashan Hospital, Fudan University. The study will collect information on nutrition, heart and bone health, cognition, and daily functioning through hospital records and a patient mobile app. The goal is to understand the links between nutrition, metabolism, and organ function, and to develop integrated strategies for early prevention and management of chronic kidney disease.
Eligibility
Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria:
1. Non-dialysis patients with chronic kidney disease (CKD) stages 1-5.
2. Aged 18 to 90 years, no restriction on gender.
3. Sufficient health literacy or a family member with adequate literacy to comply with dietary diary recording and other study procedures.
4. Stable primary disease of CKD at the time of enrollment.
Exclusion Criteria:
1. Patients with malignancies, severe cardiovascular diseases, osteoporosis, or severe hematological disorders.
2. Active infections (CRP \>10 mg/L) or current use of nephrotoxic drugs.
3. Limb paralysis or amputation.
4. Use of immunosuppressants (cyclosporine, tacrolimus) within the past 3 months or steroid therapy equivalent to prednisone \>10 mg/day.
5. Severe gastrointestinal diseases affecting nutrient absorption.
6. Participation in other diet- or drug-related clinical studies within the past month or ongoing.
7. Any other condition deemed inappropriate for participation by the investigators.
Primary outcome measure(s)
Rapid decline in renal function — eGFR will be measured at baseline and at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months, and 36 months after enrollment, and subsequently every 6 months thereafter up to 10 years of follow-up. The primary outcome is the occurrence of a rapid decline in kidney function, defined as a ≥40% decrease in estimated glomerular filtration rate (eGFR) from baseline during the follow-up period. eGFR will be calculated using the CKD-EPI formula based on serum creatinine measurements obtained during scheduled clinical visits.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.